Published in Pharma Investments, Ventures and Law Weekly, April 11th, 2004
The alliance combines Isis' intellectual property and development expertise with Alnylam's intellectual property and research expertise in RNAi therapeutics. The alliance provides Isis with an opportunity to realize significant value from its work in antisense mechanisms and oligonucleotide chemistry and strengthens Alnylam's RNAi therapeutics discovery and commercialization efforts.
"We are confident that Alnylam...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.